Drug
Ak112
Ak112: highest development phase Phase 3, developed by Akeso. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK112, Carboplatin, Paxlitaxel NCT05840016 | Phase 3 | Advanced Squamous Non Small Cell Lung Cancer |
| AK112 NCT07010263 | Phase 3 | Small Cell Lung Cancer |
| AK112 NCT07114315 | Phase 2 | Pancreatic Cancer |
| AK112 NCT05432492 | Phase 2 | Hepatocellular Carcinoma |
| AK112 NCT05247684 | Phase 2 | Resectable Non-small Cell Lung Cancer |
| AK112 NCT05214482 | Phase 1/2 | Advanced Malignant Tumors |
| AK112 NCT05229497 | Phase 1/2 | Advanced Malignant Tumors |
| AK112 (New Site) NCT07340476 | Phase 1 | Healthy Male Subjects |
Latest
No recent events.
Follow Ak112 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.